AN2 Therapeutics, Inc. (ANTX)

NASDAQ: ANTX · IEX Real-Time Price · USD
15.28
-0.19 (-1.23%)
Feb 7, 2023, 4:00 PM EST - Market closed
-1.23%
Market Cap 296.47M
Revenue (ttm) n/a
Net Income (ttm) -36.66M
Shares Out 19.40M
EPS (ttm) -12.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 29,715
Open 15.47
Previous Close 15.47
Day's Range 14.38 - 15.89
52-Week Range 6.88 - 23.58
Beta n/a
Analysts Buy
Price Target 23.80 (+55.76%)
Earnings Date Feb 8, 2023

About ANTX

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 25, 2022
Employees 26
Stock Exchange NASDAQ
Ticker Symbol ANTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ANTX stock is "Buy." The 12-month stock price forecast is $23.8, which is an increase of 55.76% from the latest price.

Price Target
$23.8
(55.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious dise...

1 week ago - Business Wire

AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

MENLO PARK, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...

3 months ago - GlobeNewsWire

AN2 Therapeutics to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...

3 months ago - GlobeNewsWire

AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022

MENLO PARK, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...

3 months ago - GlobeNewsWire

AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease

MENLO PARK, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...

4 months ago - GlobeNewsWire

NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million

NIAID Agreement to Advance Development of Epetraborole for Acute Systemic Melioidosis NIAID Agreement to Advance Development of Epetraborole for Acute Systemic Melioidosis

4 months ago - GlobeNewsWire

AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

MENLO PARK, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...

5 months ago - GlobeNewsWire

AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

MENLO PARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) --  AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious...

6 months ago - GlobeNewsWire

AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...

7 months ago - GlobeNewsWire

AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious i...

9 months ago - GlobeNewsWire

AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc., (NASDAQ: ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with hig...

9 months ago - Business Wire

RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15

AN2 Therapeutics Inc (NASDAQ: ANTX) will be offering 4.6 million shares at $15 a share in its initial public offering, under the ticker 'ANTX,' raising $69 million.  The Company announced IPO plans ea...

11 months ago - Benzinga

AN2 Therapeutics Stock to List Today

Biotech AN2 Therapeutics sold 4.6 million shares at $15 each, the mid-point of its $14 to $16 range. It's the second conventional IPO this month.

11 months ago - Barrons

AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering

MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious dis...

11 months ago - GlobeNewsWire

AN2 Therapeutics Set for a March IPO

Biotech AN2 Therapeutics will be the second company to go public through a traditional initial public offering in March.

11 months ago - Barrons